Collaborative research project led by Prof. D. Antier
Names and indications of antibodies facing regulations and pharmaceutical company practices
Abstract
The names and therapeutic indications of monoclonal antibodies must comply with current regulations, which does not prevent the development of commercial strategies around trade names. Some of these practices are based on territorial or legal considerations while others are motivated by real medical concerns. Finally, some of these have a significant financial impact on the community.